Back

First-in-man trial of b3-adrenoreceptor agonist treatment in chronic heart failure - impact on diastolic function

27 August 2022 (14:15 - 14:45)
Organised by:
Congress Presentation Part of: Chronic heart failure - New treatments and trials Pharmacotherapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Hashmat Sayed Zohori Bahrami

Steno Diabetes Center, Copenhagen, Herlev (Denmark)

4 More presentations in this session

Presentation thumbnail
The I4RON-HF study, Intravenous Iron Isomaltoside for Inpatients veRsus Outpatient Asians with Heart Failure
Doctor T. Lee (Kuala Lumpur, MY)
Abstract Slides
Presentation thumbnail
The effects of combined hyperbaric oxygenation and erythropoietin therapy in treatment of heart failure
Professor P. Mitrovic (Belgrade, RS)
Slides
Presentation thumbnail
Myeloperoxidase as therapeutic target in HFpEF
Doctor S. Lejeune (Brussels, BE)
Abstract Slides
Presentation thumbnail
Chronic mitochondrial fusion promotor as a novel pharmacological intervention to alleviate left ventricular dysfunction in rats with chronic myocardial infarction
Doctor C. Maneechote (Chiang Mai, TH)
Abstract Slides

Access the full session

Session thumbnail
Chronic heart failure - New treatments and trials

The Event

Event poster

ESC Congress 2022

27 August 2022 14:15 CET
You may be interested in
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023
thumbnail
Webinar
MRAs in heart failure: what's old is new again

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources